Assess whether to resubmit, meet, or pause the program (bfdf87)

SITUATION Scientific-advice briefing book arrived with a site-change that invalidates stability claims for CMC change-control owner. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on to resubmit, meet, or in a safety team sitting on a new disproportionate signal.

DECISION CMC change-control owner in a safety team sitting on a new disproportionate signal must choose To resubmit, meet, / Pause the program using scientific-advice briefing book after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. A site-change that invalidates stability claims is noise around an already-controlled Clinical and Evidence Strategy process in a safety team sitting on a new disproportionate signal, given scientific-advice briefing book. 2. A site-change that invalidates stability claims is the event in scientific-advice briefing book that forces To resubmit, meet, for CMC change-control owner under Pharma & Life Sciences. 3. Scientific-advice briefing book shows a one-file miss after a site-change that invalidates stability claims, not a Clinical and Evidence Strategy program failure. 4. Scientific-advice briefing book cannot decide to resubmit, meet, or yet after a site-change that invalidates stability claims; hold is the only Pharma & Life Sciences close a safety team sitting on a new disproportionate signal can defend.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 2. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a site-change that invalidates stability claims. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read scientific-advice briefing book against a site-change that invalidates stability claims and write the one fact that would move to resubmit, meet, or for CMC change-control owner.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (scientific-advice briefing book after a site-change that invalidates stability claims). The follow-on Clinical and Evidence Strategy action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in scientific-advice briefing book, then the action for CMC change-control owner - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Regulatory or exam hook Clinical and Evidence Strategy would cite - Clinical and Evidence Strategy finding in scientific-advice briefing book that a second reviewer can re-perform